Loading stock data…
PODD
$175.04+2.90 (+1.68%)
Market ClosedLast close May 1
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Insulet Corporation in the Healthcare sector is trading at $175.04. The stock is currently near its 52-week low of $158.35, remaining 37.9% below its 200-day moving average. Technical signals show neutral RSI of 34 and bearish MACD signal, explaining why PODD maintains its current current market pressure. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Oversold momentum (RSI 34) — potential for technical mean-reversion
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$175.04
Potential Downside
61.9%
Whystock Fair Value$66.62
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus23 analysts
Buy
Mean target$326.35+86.4%
Range$220.00 – $435.00
Fundamentals
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin de...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$13.63B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
55.48
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.47
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
15.58%
Volume
Today's trading volume
1.28M
Recent News
Rothschild & Co Redburn Downgrades Insulet Corporation (PODD), Cites “Eroding” Product Moats and Distribution
Insulet Corporation (NASDAQ:PODD) is one of the best medical device stocks to invest in right now. On April 24, Insulet Corporation (NASDAQ:PODD) was downgraded to Neutral from Buy by Rothschild & Co Redburn, with the firm bringing the price target on the stock down to $220 from $380. It told investors in a research note […]
PAHC vs. PODD: Which Stock Is the Better Value Option?
PAHC vs. PODD: Which Stock Is the Better Value Option?
Insulet (PODD) Ends April With Strong Analyst Sentiment Amid Strong Earnings Expectations
With one-year EPS and revenue growth estimates of 27.44% and 19.19%, respectively, Insulet Corporation (NASDAQ:PODD) earns a place on our list of the best growth stocks to buy and hold in 2026. Insulet Corporation (NASDAQ:PODD) is heading into late April 2026 with strong analyst backing. As of April 23, the majority of analysts covering the […]
1 Oversold Stock Primed to Rebound and 2 We Ignore
Hitting a new 52-week low can be a pivotal moment for any stock. These floors often mark either the beginning of a turnaround story or confirmation that a company faces serious headwinds.
2 of Wall Street’s Favorite Stocks for Long-Term Investors and 1 We Turn Down
The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these forecasts with a grain of salt because analysts typically say nice things about companies so their firms can win business in other product lines like M&A advisory.